GuruFocus·Jun 26, 2026
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR Newswire NEW
Nuvation Bio Inc.(NUVB)Earnings, Financials & Key Ratios
NUVB•NYSE
$5.67
Price updated Jul 7, 2026
AboutNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.Show more
- Revenue$63M+699.0%
- EBITDA-$191M+67.7%
- Net Income-$205M+64.0%
- EPS (Diluted)-0.60+71.6%
- Gross Margin86.58%+757.4%
- EBITDA Margin-303.56%+96.0%
- Operating Margin-338.72%+95.5%
- Net Margin-325.31%+95.5%
- ROE-53.18%+50.0%
NUVB Price & Volume
Nuvation Bio Inc. (NUVB) stock price & volume — 10-year historical chart
Loading chart...
Milestone Revenue Masks Persistent Clinical Burn Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:Clinical trial execution risk
Key Thesis Takeaways
- Nuvation Bio's financial profile is currently defined by a volatile reliance on non-recurring milestone payments, which obscures the underlying reality of its high-burn oncology development model.
- While the 2026Q1 revenue of $83.2 million provides a temporary liquidity cushion, the company's long-term viability remains tethered to the successful clinical execution of its pipeline rather than sustainable commercial operations.
- Investors should remain cautious as the $1.1 billion accumulated deficit and ongoing R&D intensity continue to pressure the firm's long-term capital structure.
Verdict Logic
the company's reliance on non-recurring revenue to offset a $35.0 million quarterly R&D spend suggests that the current 31.19 P/S ratio may not be supported by sustainable commercial growth.
NUVB Growth Metrics
Nuvation Bio Inc. (NUVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM1205.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM75.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.7%
Return on Capital
10 Years-40.63%
5 Years-40.68%
3 Years-55.78%
Last Year-42.83%
NUVB Recent Earnings
Nuvation Bio Inc. (NUVB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.01-91.7%
$0.12
Rev
$83M+25.7%
$66M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.11+0.0%
$0.11
Rev
$42M+10.7%
$38M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.16+5.9%
$0.17
Rev
$13M-64.4%
$37M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.17+0.0%
$0.17
Rev
$5M+33.4%
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.01vs $0.12-91.7% | $83Mvs $66M+25.7% |
| Q2 2026 | Mar 2, 2026 | $0.11vs $0.11+0.0% | $42Mvs $38M+10.7% |
| Q4 2025 | Nov 3, 2025 | $0.16vs $0.17+5.9% | $13Mvs $37M-64.4% |
| Q3 2025 | Aug 7, 2025 | $0.17vs $0.17+0.0% | $5Mvs $4M+33.4% |
Based on last 12 quarters of dataView full earnings history →
Latest NUVB News
Recent stock market news and headlines for Nuvation Bio Inc. (NUVB)
PRNewsWire·Jun 26, 2026
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesNEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million.
PRNewsWire·Jun 25, 2026
Nuvation Bio Announces Proposed Convertible Senior Notes OfferingNEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any.
Fool - Investing News·Jun 17, 2026
Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains MomentumClinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains.
Peers Comparison
Key metrics vs top competitors for Nuvation Bio Inc. (NUVB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.67 | $1.97B | -9.45 | 698.96% | -325.31% | -53.18% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $0.99 | $4.4M | -0.16 | — | — | -729.89% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $16.22 | $2.09B | 7.84 | 20.38% | 99.97% | 64.48% | — |
Compare NUVB vs Peers
Nuvation Bio Inc. (NUVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUVB SEC Filings & Documents
Nuvation Bio Inc. (NUVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Jan 12, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when NUVB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NUVB Frequently Asked Questions
Nuvation Bio Inc. (NUVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Nuvation Bio Inc.'s revenue?
Nuvation Bio Inc. (NUVB) reported $143.0M in revenue for fiscal year 2025.
How fast is Nuvation Bio Inc. growing?
Nuvation Bio Inc. (NUVB) grew revenue by 699.0% over the past year. This is strong growth.
Is NUVB profitable?
Nuvation Bio Inc. (NUVB) reported a net loss of $146.0M for fiscal year 2025.
Dividend & Returns
What is NUVB's return on equity?
Nuvation Bio Inc. (NUVB) has a return on equity (ROE) of -53.2%. Negative ROE indicates the company is unprofitable.
What is Nuvation Bio Inc.'s free cash flow?
Nuvation Bio Inc. (NUVB) had negative free cash flow of $126.1M in fiscal year 2025, likely due to heavy capital investments.